Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Study Identifier
192371-019
CT.gov Identifier
NCT01109056
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Eye Disease
    • Study Drug
  • cyclosporine ophthalmic emulsion 0.05%
  • Vehicle
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Have a pterygium in at least one eye that has not been previously removed with surgery
    Exclusion Criteria:
    * Uncontrolled systemic disease * Active eye disease * Current or anticipated use of topical eye medications other than artificial tears. * Anticipated wearing of contact lenses

    Protocol Summary

    This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).

    Study Locations

    Location
    Status
    Location
    Glendale, California, United States
    Status
    Not applicable
    Location
    Randwick, New South Wales, Australia
    Status
    Not applicable
    Location
    Singapore, Singapore
    Status
    Not applicable